EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer’s disease.

Continued here:
Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

Scroll to Top